Based: New York
Stock symbol: OPHT
Range: $14 to $16
IPO price: $22.00
Close Oct. 17: $28.75
Change: Up 30%
Raised: $167 million

The scoop: Ophthotech's story played well with investors. It's run by an experienced crew that worked together at Eyetech. They have an intriguing late-stage program for Fovista, a drug for wet age-related macular degeneration. The treatment centers on platelet derived growth factor instead of VEGF. And it helped that the company has been hanging on to the worldwide rights to a drug that could be injected alongside the VEGF standard. In the end, they raised about twice what they had initially projected, and the stock has had a big spike since the recent debut. Ophthotech currently has a market cap of $1 billion, making it one of the biggest benefactors of the IPO boom.

For more:
Ophthotech, Foundation Medicine loot booming biotech IPO market for $273M
Ophthotech eyes $85M IPO to fund PhIII for drug to prevent blindness
Ophthotech nabs $30M round to fund AMD trial


Suggested Articles

The drug failed a futility analysis in March, but Biogen resurrected it after factoring in data generated after the cutoff for the interim assessment.

The negative top-line data deal a big blow to the prospects of a drug analysts tipped to achieve blockbuster sales if it cleared phase 3.

Intrepida Bio launched with $9.5 million from Sofinnova and Canaan Partners to develop anti-BAG3 antibodies for the treatment of cancer.